GLP-1 S 10mg

GLP-1 S is a GLP-1 receptor agonist research analogue. Native GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. It acts on GLP-1 receptors in the pancreatic beta cells to stimulate glucose-dependent insulin secretion, in alpha cells to suppress inappropriate glucagon release, in the stomach to slow gastric emptying, and in the brain (particularly the hypothalamus and brainstem) to promote satiety and reduce food intake. The native GLP-1 peptide has an extremely short half-life of approximately 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Therapeutic analogues incorporate structural modifications — such as amino acid substitutions, acylation with fatty acid side chains, and albumin binding — to dramatically extend the circulating half-life. Semaglutide, for example, uses an Aib substitution at position 8 (conferring DPP-4 resistance) and a C-18 fatty diacid chain that enables non-covalent albumin binding, extending its half-life to approximately 7 days. Beyond metabolic effects, GLP-1 receptor agonists have demonstrated cardiovascular benefits in large clinical trials. The SUSTAIN-6 and SELECT trials showed reduced major adverse cardiovascular events (MACE) independent of glycemic control, suggesting direct cardioprotective mechanisms possibly mediated through anti-inflammatory and anti-atherosclerotic effects.

GLP-1 S is a GLP-1 receptor agonist research analogue. Native GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. It acts on GLP-1 receptors in the pancreatic beta cells to stimulate glucose-dependent insulin secretion, in alpha cells to suppress inappropriate glucagon release, in the stomach to slow gastric emptying, and in the brain (particularly the hypothalamus and brainstem) to promote satiety and reduce food intake. The native GLP-1 peptide has an extremely short half-life of approximately 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Therapeutic analogues incorporate structural modifications — such as amino acid substitutions, acylation with fatty acid side chains, and albumin binding — to dramatically extend the circulating half-life. Semaglutide, for example, uses an Aib substitution at position 8 (conferring DPP-4 resistance) and a C-18 fatty diacid chain that enables non-covalent albumin binding, extending its half-life to approximately 7 days. Beyond metabolic effects, GLP-1 receptor agonists have demonstrated cardiovascular benefits in large clinical trials. The SUSTAIN-6 and SELECT trials showed reduced major adverse cardiovascular events (MACE) independent of glycemic control, suggesting direct cardioprotective mechanisms possibly mediated through anti-inflammatory and anti-atherosclerotic effects.

Clinical trials of semaglutide used 0.25 mg to 2.4 mg weekly subcutaneous doses. Research analogues are studied at varying concentrations depending on specific modifications.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.